Array BioPharma

Array BioPharma, Inc. has appointed April H. Teitelbaum, M.D., MS, FACP, to the newly created position of vice president of clinical development, oncology. Dr. Teitelbaum will oversee the medical strategy and clinical development of the company’s oncology drug pipeline and will report to the company’s chief executive officer, Robert E. Conway.

“April’s solid track record and experience in developing new cancer drugs will be invaluable to Array as we advance our extensive drug pipeline,” said Mr. Conway. “April’s expertise in running complex clinical trials will be a competitive advantage for Array as we are on track for having five drugs in clinical development by the end of 2006.”

For the last 16 years, Dr. Teitelbaum has held positions of increasing responsibility for clinical and strategic development of oncology therapeutics at several pharmaceutical and biotechnology companies including Amgen, Sequus Pharmaceuticals, Ligand, Johnson and Johnson, and Kyowa Pharmaceuticals. She has been involved in clinical development, including registration strategies and expansion of label for multiple oncology therapeutics, including Neupogen, Doxil, and Yondelis. Dr. Teitelbaum also headed her own consulting company and has served as a consultant to several companies for development of novel oncology therapeutics. Prior to that Dr. Teitelbaum was engaged in private practice, specializing in Hematology and Medical Oncology.